BofA raised the firm’s price target on Teva to $15 from $14 and keeps a Buy rating on the shares. The firm, which forecasts Q4 sales and EBITDA that are slightly higher and roughly in-line versus consensus, respectively, cites a valuation multiple re-rate for its higher target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA: